RxDoctor Payments Data

Heather Wilhelm

Psychiatric/Mental Health · Omaha, NENPI 1619035425

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,375 of the $5,226 with a category attached, or 64.6%. AbbVie accounts for 68.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $4,137 and has fallen 87.9% since, to $501 in 2025.

$5,226in general payments, 2019–2025

Across 96 payments — averaging $54.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Lundbeck LLC$279
  • Johnson & Johnson$120
  • Idorsia Pharmaceuticals US Inc$57
  • Vanda Pharmaceuticals Inc.$45
  • plus $63 from 3 others

What the payments were for

  • Speaking & faculty fees$3,37565%
  • Travel & lodging$461%
  • Food & beverage$1,80535%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,226 in reported general payments places this provider in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$22,566
Medicare patients
46
Services billed
227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole41$130,463
VraylarCariprazine Hcl56$99,114
Aripiprazole166$26,010
TrintellixVortioxetine Hydrobromide33$21,668
Clozapine OdtClozapine12$12,717
VyvanseLisdexamfetamine Dimesylate29$10,915
Paliperidone ErPaliperidone25$8,760
Lurasidone Hcl22$6,995
Adzenys Xr-OdtAmphetamine12$5,857
Divalproex Sodium ErDivalproex Sodium40$5,394
LexaproEscitalopram Oxalate12$5,345
Bupropion XlBupropion Hcl225$4,950
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine74$3,955
Risperidone82$3,756
Vilazodone Hcl35$3,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$3,576$104,45968 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →